The real-world PFS finding of 9.4 months is consistent with those of pembrolizumab in the pivotal phase 3 KEYNOTE-024 trial (10.3 months) and in the subgroup of previously untreated NSCLC with PD-L1 score ≥ 1% in KEYNOTE-042 trial (7.1 months) [11,12], noting the shorter follow-up in this descriptive analysis. Here, CD274 is linked to non-small cell lung carcinoma.